Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study-Reference-Cited by-同舟云学术

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study

Published:2013-06-08 Issue:9 Volume:260 Page:2286-2296
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Hutchinson Michael,Fox Robert J.,Miller David H.,Phillips J. Theodore,Kita Mariko,Havrdova Eva,O’Gorman John,Zhang Ray,Novas Mark,Viglietta Vissia,Dawson Katherine T.

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

http://link.springer.com/content/pdf/10.1007/s00415-013-6968-1.pdf

Reference28 articles.

1. US Food and Drug Administration (2013) TECFIDERA™ prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204063lbl.pdf . Accessed 2 April 2013

2. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O’Neill GN (2008) Efficacy and safety of oral fumarate in patients with relapsing–remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372:1463–1472

3. Gold R, Kappos L, Arnold DL, Bar-Or A, Giavannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT, On behalf of the DEFINE Study Investigators (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367:1098–1107

4. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, On behalf of the CONFIRM Study Investigators (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367:1087–1097

5. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707–717

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations;Multiple Sclerosis Journal;2024-09-08

2. Real-world effectiveness of disease-modifying therapies in older adults with multiple sclerosis;Journal of Medicine, Surgery, and Public Health;2024-08

3. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-01-04

4. Association between age and inflammatory disease activity on magnetic resonance imaging in relapse onset multiple sclerosis during long‐term follow‐up;European Journal of Neurology;2023-05-26

5. Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis;Journal of Neurology, Neurosurgery & Psychiatry;2023-05-12